Christopher Pierce is VP at Prelude Therapeutics Inc (PRLD). They have made 3 open-market trades across 1 company since 2020, most recently 2021-09-02.
CIK 0001824631
1 open-market purchase totalling $71K since 2020, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PRLD | 17,407 | $56K |
Shares reported on the most recent Form 4, priced at the 2021-09-07 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PRLD | SELL | 2021-09-02 | 2021-09-07 | $41.47 | $1.1M | -7.4% | -54.4% | -63.6% |
| PRLD | SELL | 2021-04-29 | 2021-04-30 | $40.29 | $266K | +7.9% | -19.7% | -20.3% |
| PRLD | SELL · 10b5-1 | 2021-04-08 | 2021-04-15 | $40.00 | $8K | +5.2% | +23.6% | -23.7% |
| PRLD | SELL · 10b5-1 | 2021-04-07 | 2021-04-09 | $40.08 | $33K | +1.5% | +16.4% | -21.1% |
| PRLD | BUY | 2020-09-29 | 2020-09-29 | $19.00 | $71K | +53.5% | +22.5% | +195.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.